8/12/2019 Viral Load Statement July 2014

http://slidepdf.com/reader/full/viral-load-statement-july-2014 1/2

 

Treatment Action Campaign • Treatment Action Group • HIV iBase • International Treatment Preparedness Coalition(ITPC) • Health GAP • AIDS and Rights Alliance of Southern Africa (ARASA) • Asian Network of People Living with

HIV/AIDS (ANP+) • MSF Access Campaign • AfroCAB • International Community of Women Living with HIV/AIDS East Africa (ICW EA) • AIDS Law Project, Kenya • Housing Works • TASO Uganda • Zimbabwe Network of People Living with

HIV/AIDS (ZNNP+) • Positive Generation Cameroon • International Civil Society Support • Thai AIDS Treatment ActionGroup (TTAG) • Thai Network of People Living with HIV (TNP+) • ACCESS Foundation Thailand • Delhi Network of

People Living with HIV (DNP+) • National Network of Tanzanian Women with HIV/AIDS • Africa Young Positives (AY+)• Africa Japan Forum • Japan AIDS and Society Association (JASA) • Gays and Lesbians of Zimbabwe • Treatment

 Advocacy and Literacy Campaign (TALC), Zambia • Coalition for Health Promotion and Social Development (HEPS)Uganda • DRC National Grassroots Association of People Living with HIV • Zimbabwe HIV/AIDS Activist Union

Community Trust (ZHAAUCT) • Ngibalulekile • Services for Health in Asian and African Regions (SHARE) • RedeNacional de Asoociaçiões de Pessaoas Vivendo Com HIV/SIDA • National Association of People Living with HIV,

Mozambique (ENSIDA) • Movement for Access to Treatment In Mozambique (MATRAM) • Mozambique Association of AIDS Service Organizations (MONASO) • Mozambique Network of NGOs working In Health and HIV/AIDS (NAIMA+)

"#$%&'&(')*+&, -./)+ +0)%10220/'3$.'4 50/ )++ *4 67678

"# $%&& '() %* %+,-.-(/0 .%)1#. (' /*2#.#$.%,&# 3-)%& &(%2 .( '()+ .4# $()# (' *#5 1&(,%& 1(%&0 ,#-*12#,%.#2 ,6 7*-.#2 8%.-(*0 -*0.-./.-(*0 %*2 *%.-(*%& 1(3#)*+#*.0 %*2 2#+%*2 *(. 9/0. .4# :)(+-0#0 ,/.

.4# '/*2-*1; .)#%.+#*. (:.-(*0; &%50 %*2 :(&-$-#0 *##2#2 .( +##. .4(0# .%)1#.0<

=( %$4-#3# 0/$$#00 -* .4# '-14. %1%-*0. .4# >?@ #:-2#+-$; )#:().-*1 %*2 .)%$A-*1 >?@ .#0.-*1 %*2 .)#%.+#*.

%0 0/$$#00 -*2-$%.()0 %)# 0-+:&6 *(. 1((2 #*(/14< "# *##2 .( A*(5 4(5 5#&& >?@B:(0-.-3# :#(:&# %)#

%$./%&&6 2(-*1< C/))#*.&6; )#%$4-*1 %*2 +%-*.%-*-*1 %* D/*2#.#$.%,&# 3-)%& &(%2E -0 .4# $&(0#0. .4-*1 5# 4%3#

.( % $/)# '() >?@< =4# ,#0. +#%0/)# (' 54#.4#) >?@ -0 ,#-*1 0/::)#00#2 -* %* >?@B:(0-.-3# :#)0(*F0 ,(26 -0 %

3-)%& &(%2 .#0.< G/)%,&# 0/::)#00-(* (' >?@ 4#&:0 >?@ :(0-.-3# :#(:&# 0.%6 %&-3# %*2 4#%&.46 54-&# %&0(

4#&:-*1 :)#3#*. >?@ .)%*0+-00-(* .4)(/14 0#H; -*9#$.-*1 2)/1 /0#; %*2 2/)-*1 :)#1*%*$6; &%,(/) %*2

,)#%0.'##2-*1<

AY+ African YoungPositives Network 

2 2

International Civil Society Support

8/12/2019 Viral Load Statement July 2014

http://slidepdf.com/reader/full/viral-load-statement-july-2014 2/2

 

I#. .(2%6 +(0. :#(:&# &-3-*1 5-.4 >?@ (/.0-2# 5#%&.46 $(/*.)-#0 2(*F. A*(5 .4#-) 3-)%& &(%2 %*2 .(( +%*6

2( *(. 4%3# .4# .)#%.+#*. .4#6 *##2 .( $(*.)(& .4# 3-)/0J('.#* ,#$%/0# .4#6 2( *(. #3#* 4%3# %$$#00 .(

.#0.-*1< =4-0 -0 % 3-(&%.-(* (' ,%0-$ 4/+%* )-14.0J%&& :#(:&# 2#0#)3# .4# -*'()+%.-(*; +#2-$-*#; %*2 0/::().

*##2#2 .( $(*.)(& %*2 0/::)#00 .4# 3-)/0<

"# +/0. .4#)#'()# ,# +(*-.()-*1 3-)%& &(%2 0/::)#00-(* )%.#0 .( #*0/)# >?@ .)#%.+#*. :)(1)%++#0 %)#

2#&-3#)-*1 +%H-+/+ -+:%$. '() >?@ :(0-.-3# :#(:&#< @-)%& &(%2 .#0.0 %)# %&0( )#$(++#*2#2 '() .4# (:.-+%&

+%*%1#+#*. (' :#(:&# )#$#-3-*1 %*.-)#.)(3-)%& .)#%.+#*.< =4# "()&2 >#%&.4 K)1%*-L%.-(* )#$(++#*20

)(/.-*# 3-)%& &(%2 +(*-.()-*1 .( #*0/)# %*.-)#.)(3-)%& .)#%.+#*. -0 5()A-*1 %*2 .( #*0/)# .-+#&6 %*2

%$$/)%.# 2#.#$.-(* (' .)#%.+#*. '%-&/)#<

?* %22-.-(*; .4# $(0.B#''#$.-3#*#00 (' 3-)%& &(%2 .#0.-*1 -0 -+:)(3-*1 %*2 *#5 .#$4*(&(1-#0 :)(+-0# '/).4#)

:)-$# )#2/$.-(*0; %&(*1 5-.4 #H:%*2-*1 #$(*(+-#0 (' 0$%&#< "# 2( *(. $(*0-2#) $(0. .( ,# % 0/''-$-#*.

#H$/0# '() '%-&-*1 .( (''#) #3#)6 :#)0(* (* %*.-)#.)(3-)%& .)#%.+#*. (* .4# :&%*#. %* %**/%& 3-)%& &(%2 .#0. ,6

MNMN< "# %&0( 2( *(. $(*0-2#) % &%$A (' $/))#*. .#0.-*1 $%:%$-.6 -* 0(+# 2#3#&(:-*1 $(/*.)-#0 .( ,# #-.4#)

%* -*0/)+(/*.%,&# (,0.%$&# () %* %$$#:.%,&# #H$/0#< "4#* OP@ .)#%.+#*. 5%0 -*.)(2/$#2 -* .4# #%)&6

MNNN0; 0$#:.-$0 %)1/#2 .4%. :)(3-2-*1 .)#%.+#*. -* )#0(/)$#B&-+-.#2 0#..-*10 5(/&2 ,# -+:(00-,&# 2/# .(

$(0.; $(+:&#H-.6 %*2 &%$A (' .#$4*-$%& $%:%$-.6<=4# 0%+# %)1/+#*.0 %)# ,#-*1 /0#2 .(2%6 )#1%)2-*1 3-)%&

&(%2 +(*-.()-*1; #3#* .4(/14 .4# ,#*#'-.0 (' .4# .#$4*(&(16 %)# -*2-0:/.%,&#<

"# A*(5; .((; .4%. 3-)%& &(%2 +(*-.()-*1 -0 9/0. (*# :-#$# (' .4# :/LL&#< =( %$4-#3# /*2#.#$.%,&# .%)1#.0

&#%2#)0 +/0. $(++-. .(Q

•  #9.$: &-&/4 '00+ )-).+)*+& '0 &+.;.$)'& 2)'&$' *)//.&/9 '<)' ;)=& >?@9 )$% 0'<&/ %/3:9

3$)550/%)*+& .$ ;)$4 (03$'/.&9A

•  B0 9.$:+& -./)+ +0)% '&9' )$4C<&/& .$ '<& C0/+% 9<03+% (09' ;0/& '<)$ D7 #EF )$% 53/'<&/ 2/.(&

/&%3('.0$9 9<03+% *& 2099.*+&A

•  G3++4 53$%.$: '<& HI@ '/&)';&$' /&920$9& .$(+3%.$: 53++4 53$%.$: $)'.0$)+ 2/0:/);9J '<& K+0*)+

G3$%J LMLG>?J )$% 0'<&/ .$.'.)'.-&9A

•  G3++4 53$%.$: 9'/0$:J )((03$')*+&J (0;;3$.'4N*)9&% '/&)';&$' +.'&/)(4 )$% )%<&/&$(& 93220/'

)+0$: C.'< 9'/0$: 90(.)+ 2/0'&('.0$ 2/0:/);9A

•  O0;;.''.$: '0 ) <3;)$ /.:<'9 *)9&% HI@ /&920$9& *4 (0;*)'.$: (/.;.$)+.P)'.0$J %.9(/.;.$)'.0$J

)$% 9'.:;) )$% )-&/'.$: (0&/(.-& 2/)('.(&9 *4 23''.$: .$ 2+)(& ) 9'/0$: (0;;3$.'4 +&% /.:<'9

.$5/)9'/3('3/&A

?' 7*-.#2 8%.-(*0 %1#*$-#0 %*2 *%.-(*%& 1(3#)*+#*.0 %)# 0#)-(/0 %,(/. .)/&6 ./)*-*1 .4# .-2# %1%-*0. .4#

>?@ #:-2#+-$; .4#6 5-&& 0#. %+,-.-(/0 3-)%& &(%2 0/::)#00-(* .%)1#.0 %*2 #*0/)# .4%. #3#)6(*# 4%0 .4#(::()./*-.6 .( 4%3# %* R/*2#.#$.%,&#F 3-)%& &(%2< =4# .%)1#. 5# 5%*. -0 %0 '(&&(50Q DO. &#%0. SNT (' %&&

.)#%.+#*. #&-1-,&# >?@B:(0-.-3# :#)0(*0 +/0. 4%3# /*2#.#$.%,&# 3-)%& &(%20 ,6 MNMN U:#)0(*0 54( 2-2 *(.

4%3# 3-)%& &(%2 .#0.0 -* .4# :)#$#2-*1 VM +(*.40 +/0. ,# $(*0-2#)#2 *(. .( ,# 3-)%&&6 0/::)#00#2W<EV 

" At least 80% of ALL treatment eligible people must have undetectable viral loads by 2020, which means a significant

increase in voluntary HIV testing and enrollment on treatment and care programs, reflecting that 90% of people

eligible for ART have access, and 90% of people on ART reach and maintain an undetectable viral load.